Binimetinib
Kinase inhibitor Mechanism of Action Pharmacokinetics Binding Mode- Product Name
- Binimetinib
- CAS No.
- 606143-89-9
- Chemical Name
- Binimetinib
- Synonyms
- MEK162;ARRY-162;ARRY-438162;CS-394;ARRY 162;Binimetinib;MEK162, ARRY-162;Valine Impurity 34;MEK162(Binimetinib);MEK162 (ARRY-438162)
- CBNumber
- CB82604200
- Molecular Formula
- C17H15BrF2N4O3
- Formula Weight
- 441.23
- MOL File
- 606143-89-9.mol
Binimetinib Property
- Melting point:
- >203oC (dec.)
- Density
- 1.67
- storage temp.
- -20°C
- solubility
- Soluble in DMSO (up to at least 25 mg/ml)
- pka
- 14.20±0.10(Predicted)
- form
- solid
- color
- White
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
- InChI
- InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
- InChIKey
- ACWZRVQXLIRSDF-UHFFFAOYSA-N
- SMILES
- C1N(C)C2=CC(C(NOCCO)=O)=C(NC3=CC=C(Br)C=C3F)C(F)=C2N=1
Safety
- HS Code
- 2933998090
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Danger
- Hazard statements
-
H360May damage fertility or the unborn child
H362May cause harm to breast-fed children
- Precautionary statements
-
P201Obtain special instructions before use.
P260Do not breathe dust/fume/gas/mist/vapours/spray.
P263Avoid contact during pregnancy/while nursing.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P308+P313IF exposed or concerned: Get medical advice/attention.
N-Bromosuccinimide Price
- Product number
- SML3385
- Product name
- Binimetinib
- Purity
- ≥98% (HPLC)
- Packaging
- 10MG
- Price
- $51.6
- Updated
- 2025/07/31
- Product number
- SML3385
- Product name
- Binimetinib
- Purity
- ≥98% (HPLC)
- Packaging
- 50MG
- Price
- $168
- Updated
- 2025/07/31
- Product number
- 16996
- Product name
- Binimetinib
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $57
- Updated
- 2024/03/01
- Product number
- 16996
- Product name
- Binimetinib
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $107
- Updated
- 2024/03/01
- Product number
- 16996
- Product name
- Binimetinib
- Purity
- ≥98%
- Packaging
- 50mg
- Price
- $437
- Updated
- 2024/03/01
Binimetinib Chemical Properties,Usage,Production
Kinase inhibitor
Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor with potential antineoplastic activity.
Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor.
Mechanism of Action
Binimetinib is a reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. In vitro, binimetinib inhibited extracellular signal-related kinase (ERK) phosphorylation in cellfree assays as well as viability and MEK-dependent phosphorylation of BRAF-mutant human melanoma cell lines. Binimetinib also inhibited in vivo ERK phosphorylation and tumor growth in BRAF-mutant murine xenograft models.
Pharmacokinetics
The primary metabolic pathway is glucuronidation with UGT1A1 contributing up to 61% of the binimetinib metabolism. Other pathways of binimetinib metabolism include N-dealkylation, amide hydrolysis, and loss of ethane-diol from the side chain. The active metabolite M3 produced by CYP1A2 and CYP2C19 represents 8.6% of the binimetinib exposure. Following a single oral dose of 45 mg radiolabeled binimetinib, approximately 60% of the circulating radioactivity AUC in plasma was attributable to binimetinib.
Binding Mode
As shown in the co-crystal structure of
binimetinib in complex with BRAF–MEK1 kinases
and AMP–PNP (Fig. 1), the imine nitrogen of the
benzo[d]imidazole core hydrogen bonds to both the
amide NH of Ser212 and amide NH of Val211, and
the amide oxygen also forms a hydrogen bond with
the primary amine of Lys97. In addition, the terminal
hydroxyl group hydrogen bonds to the α-phosphate
oxygen of AMP–PNP. Also, the carboxamide side
chain oxygen interacts indirectly with the carboxylic
acid of Asp208 and AMP–PNP via a water molecule
(Fig. 2).
Description
Binimetinib (606143-89-9) is a potent (IC50?= 12 nM) and selective allosteric inhibitor of MEK1/2.1,2?Recently approved by the FDA for treatment of melanoma in combination with Encorafenib. Binimetinib has had limited success as monotherapy but has shown promise in combination with other chemotherapeutic agents.3-5
Uses
MEK 162 is a MEK1/2 inhibitor allowing it to be a effective anti-cancer medication.
Definition
ChEBI: Binimetinib is a member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of benzimidazoles, a member of bromobenzenes, a member of monofluorobenzenes, a hydroxamic acid ester and a secondary amino compound.
brand name
Mektovi
General Description
Class: dual threonine/tyrosine kinase; Treatment: melanoma with BRAF mutations; Other name: ARRY-162; Oral bioavailability = 50%; Elimination half-life = 3.5 h; Protein binding = 97%
Pharmacokinetics
After oral administration, binimetinib is absorbed rapidly, with a median tmax of 1.48 h. Binimetinib is 50% orally bioavailable and exhibits a short elimination half-life of 3.5 h. Consequently, it requires twice-daily dosing regimen. Binimetinib undergoes UGT1A1-mediated glucuronidation, which contributes up to 61% of the overall metabolism. Other metabolic pathways include N-dealkylation, amide hydrolysis, and loss of ethanediol from the side chain.
target
Primary target: MEK1/2
References
[1] PATRICE A LEE. Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor[J]. Cancer research, 2010, 70 1: 2515-2515. DOI:10.1158/1538-7445.am10-2515
[2] S. WINSKI. 162 MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations[J]. Ejc Supplements, 2010, 8 1: 56. DOI:10.1016/s1359-6349(10)71867-x
[3] MICHAEL S LEE. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.[J]. Oncotarget, 2016: 39595-39608. DOI:10.18632/oncotarget.9153
[4] JUN GONG. MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.[J]. Anticancer research, 2017, 37 6: 2831-2838. DOI:10.21873/anticanres.11634
[5] ERIC VAN CUTSEM. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.[J]. Journal of Clinical Oncology, 2019, 37 17: 1460-1469. DOI:10.1200/jco.18.02459
Binimetinib Preparation Products And Raw materials
Raw materials
Preparation Products
Binimetinib Suppliers
- Tel
- 19982073091
- 2538834896@qq.com
- Country
- China
- ProdList
- 77
- Advantage
- 58
- Tel
- Fax
- 86-21-57758967
- sales@boylechem.com
- Country
- China
- ProdList
- 2922
- Advantage
- 55
- Tel
- +86-21-20908456
- Fax
- 021-58180499
- sales@BioChemBest.com
- Country
- China
- ProdList
- 6003
- Advantage
- 61
- Tel
- 28-83379370 13880556291
- Fax
- 028-87747383
- tcy@tcypharm.com
- Country
- China
- ProdList
- 510
- Advantage
- 57
- Tel
- 0531-88811783
- Fax
- +86 (531) 55696010 QQ 1762738062
- sales@trio-pharmatech.com
- Country
- China
- ProdList
- 1856
- Advantage
- 62
- Tel
- 27-027-83314682 13554138826
- Fax
- +86 (27) 8331-4682
- whsrtech@vip.163.com
- Country
- China
- ProdList
- 246
- Advantage
- 62
- Tel
- 021-50460086-9 15921403865
- Fax
- +86-21-50462321
- han_yajun@dctc.daicel.com
- Country
- China
- ProdList
- 7471
- Advantage
- 65
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
- Country
- China
- ProdList
- 4747
- Advantage
- 58
- Tel
- 021-58170097
- info@topbiochem.com
- Country
- China
- ProdList
- 9510
- Advantage
- 58
- Tel
- 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
- Fax
- +86-27-87599188
- Country
- China
- ProdList
- 1493
- Advantage
- 55
View Lastest Price from Binimetinib manufacturers
- Product
- Binimetinib
- Price
- US $0.00-0.00/kg
- Min. Order
- 1kg
- Purity
- 99%
- Supply Ability
- 1
- Release date
- 2025-08-22
- Product
- Binimetinib 606143-89-9
- Price
- US $0.00/g
- Min. Order
- 1g
- Purity
- More Than 99%
- Supply Ability
- 100kg/Month
- Release date
- 2024-10-14
- Product
- Binimetinib 606143-89-9
- Price
- US $0.00-0.00/kg
- Min. Order
- 1kg
- Purity
- 99%, Single impurity＜0.1
- Supply Ability
- 1 ton
- Release date
- 2023-12-23